(MedPage Today) — The FDA said Friday it will offer ultra-fast review to three psychedelic drugs being developed for hard-to-treat forms of depression and post-traumatic stress disorder (PTSD), the latest step by the Trump administration toward…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
